U.S. Antimony Stock: A Tale of Conflicting Signals

U.S. Antimony shares are caught in a fundamental tug-of-war. On one hand, substantial long-term contracts valued at over $351 million paint a promising future. On the other, disappointing quarterly earnings have triggered significant downward pressure on the stock price. The equity recently declined by 5.58 percent to settle at $7.62, marking a 9.29 percent drop over a ten-day period.

Robust Long-Term Contracts Establish Strong Foundation

The company’s long-term outlook has been fundamentally reshaped by two major agreements. The U.S. Department of Defense initiated a five-year deal for antimony supplies worth $245 million. This was immediately followed by a second five-year contract with a major industrial corporation valued at $106.7 million. Combined, these agreements create a contracted revenue pipeline exceeding $351 million, establishing a solid operational foundation for the coming years.

Quarterly Results Disappoint Against Strong Nine-Month Performance

The third quarter of 2025 proved challenging for U.S. Antimony, with financial results falling short of projections. Revenue remained at $8.7 million, significantly below the anticipated $13 million. However, a broader view reveals a different story. For the nine-month period ending in September, the company demonstrated impressive growth momentum. Revenue surged by 182 percent to $26.23 million, while the gross margin expanded from 24 to 28 percent. Although the company reported a net loss of $4.05 million, a substantial portion of this was attributed to non-cash expenses.

Operational Expansion Gains Momentum

Production capacity is visibly increasing. Since October, more than 560 tons of antimony ore have been transported from the reopened mine in Montana. This domestic production is expected to significantly enhance profit margins starting in early 2026. Concurrently, the expansion of the Thompson Falls smelter is advancing steadily. The project is currently 65 percent complete and is projected to achieve a monthly production rate exceeding 500 tons of antimony upon its scheduled 2026 completion.

Should investors sell immediately? Or is it worth buying US Antimony?

Technical Indicators Flash Warning Signs

Chart analysis presents clear cautionary signals for investors. The stock has been in a sustained downtrend since generating a pivot top signal on October 14th, reinforced by a sell signal from the 3-month MACD indicator. Trading at $7.62, the shares sit well below their 52-week high of $19.70, though they remain substantially above their low of $0.49. A trading volume that tripled during the price decline underscores the prevailing selling pressure.

Despite these short-term headwinds, the company’s balance sheet remains sturdy. With $38.5 million in cash reserves, minimal long-term debt, and a market capitalization of $1.07 billion, U.S. Antimony maintains a solid financial base. Nevertheless, declining global antimony prices and ongoing logistical challenges could potentially delay a meaningful recovery in the near term.

The critical question for investors remains whether the company’s operational expansion can successfully keep pace with the substantial contractual commitments it has secured.